Tissue specific cytotoxicity of colon cancer cells mediated by nanoparticle-delivered suicide gene in vitro and in vivo

Clinical Cancer Research

Volumn 15, Issue 1, 2009, Pages 201-207

  Zhang, Guiying ^a   Liu, Ting ^a   Chen, Yong Heng ^c   Chen, Yuxiang ^b   Xu, Meihua ^a   Peng, Jie ^a   Yu, Shuyi ^b   Yuan, Jianwei ^a   Zhang, Xiuwu ^a,d  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM PHOSPHATE; CARCINOEMBRYONIC ANTIGEN; CYTOSINE DEAMINASE; FLUOROURACIL; NANOCARRIER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GENE THERAPY; COLON CARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; GENE CONSTRUCT; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROMOTER REGION; SUICIDE GENE; THERAPY EFFECT; TISSUE SPECIFICITY; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CALCIUM PHOSPHATES; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYTOSINE DEAMINASE; FLUOROURACIL; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HUMANS; MICE; MICE, NUDE; NANOPARTICLES; PROMOTER REGIONS, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58849088990     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1094     Document Type: Article

References (41)

1. Li Y, Chen Y, Dilley J, et al. Carcinoembryonic antigen- producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy. Mol Cancer Ther 2003; 2:1003-9.
2. Keighley MRB. Gastrointestinal cancers in Europe. Aliment Pharmacol Ther 2003;18:7-30.
3. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003,95: 1276-99.
4. Freeman SM, Whartenby KA, Freeman JL, Abboud CN, Marrogi AJ. In situ use of suicide genes for cancer therapy. Semin Oncol 1996;23:31 -45.
5. Moolten FL, Wells JM, Heyman RA, Evans RM, Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum Gene Ther1990;1:125-34.
6. Kievit E, Bershad E, Ng E, et al. Superiority of yeast over bacterial cytosine deaminase for enzyme/ prodrug gene therapy in colon cancer xenografts. Cancer Res 1999;59:1417-21.
7. Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A 1994; 91:8302-6.
8. Namba H, Iwadate Y, Tagawa M, et al. Evaluation of the bystander effect in experimental brain tumors bearing herpes simplex virus-thymidine kinase gene by serial magnetic resonance imaging. Hum Gene Ther 1996;7:1847-52.
9. Mullen CA, Coale MM, Lowe R, Blaese RM. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fuorocytosine and induce protective immunity to wild-type tumor. Cancer Res 1994;54:1503-6.
10. Rogulski KR, Kim JH, Kim SH, Freytag SO. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum Gene Ther 1997;8:73 -85.
11. NagataT, Nakamori M, Iwahashi M, Yamaue H. Over- expression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5-deoxy-5-fluorouridine in tumour cells in vitro and in vivo Eur J Cancer 2002;38:712-7.
12. Nyati MK, Sreekumar A, Li S, et al. High and selective expression of yeast cytosine deaminase under a carcinoembryonic antigen promoter-enhancer. Cancer Res 2002;62:2337-42.
13. Mrsny RJ. Tissue- and cell-specific targeting for the delivery of genetic information. In: Amiji MM, editor Polymeric gene delivery: principles and applications. LLC, Boca Raton (FL): CRC Press; 2004. p. 5-27.
14. Somia N, verma IM. Gene-therapy: trials and tribulations. Nat Rev Genet 2000;1:91 - 9.
15. Cavazzano-Calvo M, Thrasher A, Mavilio F. The future of gene therapy. Nature 2004;427:779 81.
16. Ma H, Diamond SL. Nonviral gene therapy and its delivery systems. Curr Pharm Biotechnol 2001; 2:1-17.
17. Nishikawa M, Hashida M. Nonviral approaches satisfying various requirements for effective in vivo gene therapy. Biol Pharm Bull 2002;25:275-83.
18. Panyam J, Labhasetwar V. Biodegradable nanoparticies for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003;55:329-52.
19. Kaul G, Amiji M. Tumor-targeted gene delivery using poly ethylene glycol-modified gelatin nanoparticies: in vitro and in vivo studies. Pharm Res 2005; 22:951-61.
20. Roy I, Mitra S, Maitra A, Mozumdar S. Calcium phosphate nanoparticies as novel non-viral vectors for targeted gene delivery. Int J Pharm 2003;250: 25-33.
21. Bharali DJ, Klejbor I, Stachowiak EK, et al. Organically modified silica nanoparticies: a nonviral vector for in vivo gene delivery and expression in the brain, Proc Natl Acad Sci U S A 2005;102:11539-44.
22. Liu T, Tang A, Zhang G, et al. Calcium phosphate nanoparticies as a novel nonviral vector efficient transfection of DNA in cancer gene therapy. Cancer Biother Radiopharm 2005;20:141 -9.
23. Maitra A. Calcium phosphate nanoparticies: second-generation nonviral vectors in gene therapy. Expert Rev Mol Diagn 2005;5:893-905.
24. Han S, Mahato Rl, Sung YK, Kim SW. Development of biomaterials for gene therapy. Mol Ther 2000;2: 302-17.
25. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J 2005; 19:311 -30.
26. Colvin VL. The potential environmental impact of engineered nanomaterials. Nat Biotechnol 2003;21: 1166-70.
27. Chen YH, Yang CK, Xia M, Ou CY, Stallcup MR. Role of GAC63 in transcriptional activation mediated by (5-catenin. Nucleic Acids Res 2007;35:2084-92.
28. Chen YH, Beischlag TV, Kim JH, Perdew GH, Stallcup MR. Role of GAC63 in transcriptional activation mediated by the Aryl hydrocarbon receptor. J Biol Chem 2006;281:12242-7.
29. Tiraby M, Cazaux C, Baron M, Drocourt D, Reynes JP, Tiraby G. Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. FEMS Microbiol Lett 1998;167:41 -9.
30. Richards CA, Austin EA, Huber BE. Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 1995;6: 881-93.
31. Adachi Y, Tamiya T, Ichikawa T, et al. Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferasegene with 5-fluorocytosine. Hum GeneTher 2000;11:77-89.
32. Miyagi T, Koshida K, Hori 0, et al. Gene therapy for prostate cancer using the cytosine deaminase/uracil phosphoribosyltransferasesuicide system. J Gene Med 2003;5:30-7.
33. Link CJ, Kolb EM, Muldoon RR. Preliminary in vitro efficacy and toxicity studies of the herpes simplexthymidine kinase gene system for the treatment of breast can-cer. Hybridoma 1995;14: 143-7.
34. Mullen CA, Coale MM, Lowe R. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with5-fluorocytosine and induce protective immunity to wild-type tumor. Cancer Res 1994;54: 1503-6.
35. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenovirus for gene therapy. Proc Natl Acad Sci US A 1994;91:4407-11.
36. Engelhardt JE, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviuses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A 1994;91:6196-200.
37. Tenenbaum L, Lehtonen E, Monahan PE. Evaluation of risks related to the use of adeno-associated virus- based vectors. Curr GeneTher 2003;3:545 - 65.
38. Dellian M, Yuan F, Trubetskoy VS. Torchilin VP, Jain PK. Vascular permeability in a human tumor xenograft: molecular charge dependence. Br J Cancer 2000;82: 1513-8.
39. Shvedova AA, Castranova V, Kisin ER, Schwegler- Berry D, Murray AR, Gandelsman VZ, et al. Exposure to carbon nanotube material: assessment of nanotube cytotoxicity using human keratinocyte cells. J Toxicol Environ Health 2003;66:1909-26.
40. He XW, Liu T, Chen YX, et al. Calcium carbonate nanoparticle delivering vascular endothelial growth factor-C si RNA effectively inhibits lymphangiogenesis and growth of gastric cancer in vivo. Cancer Gene Ther 2008;15:193-202.
41. Brannon-Peppas L, Blanchette LQ. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004;56:1649-59.